Eris Lifesciences Share Price

ERIS Lifesciences Limited, with its corporate operations in Ahmedabad, functions as a branded pharmaceutical formulations company in India. The company was incorporated in 2007 and is among the top 20 pharmaceutical companies in the country and the youngest one in this elite list. ERIS Lifesciences manufactures a wide range of prescription products across several dosage forms, including oral solids, oral liquids, softgels, ointments, sprays and gels, sterile injectables and biologics, with a total of six manufacturing facilities. The company operates from its headquarters in Ahmedabad, Gujarat and is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model, serving as a fully-integrated pan-India business with a strong focus on high-end super-specialist doctors and consulting physicians. 

ERIS Lifesciences share price today on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the healthcare sector. The company’s financial health depends on prescription volumes from super-specialist doctors, raw material costs including active pharmaceutical ingredients, capacity utilization rates across its manufacturing facilities, domestic demand from patients, and the performance of its chronic and acute therapy segments. ERIS Lifesciences stock price is influenced by various factors such as earnings reports, drug pricing regulations from the National Pharmaceutical Pricing Authority, regulatory changes in the pharmaceutical industry, and global API price trends. In the longer run, strategies such as expansion into new therapeutic areas like oncology and biologics, acquisitions of complementary brands and businesses, and patient care initiatives affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

ERIS Lifesciences live share price provides real-time information about the last price traded, bid and ask prices, and volume traded on both the NSE and BSE exchanges. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and pharmaceutical sector news. Constant monitoring of the ERIS Lifesciences live price helps in observing short term price volatility and shows how the stock moves relative to the broader Nifty Pharma index. Furthermore, monitoring ERIS Lifesciences share price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. 

ERIS Lifesciences stock price movements allow market participants to evaluate short-term performance and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. The company has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women‘s Health, Oncology and Critical Care, and markets these products across India through a network of stockists and retail pharmacies. ERIS Lifesciences continues to focus on lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others as its core business segments, adopting business models that generate required returns while maintaining scientific excellence and regulatory compliance. 

ERIS Lifesciences Limited Company Fundamentals 

a. Company Background

ERIS Lifesciences Limited was incorporated in 2007 and is promoted by Mr. Amit Indubhushan Bakshi, with its registered office in Ahmedabad, Gujarat. The company was originally incorporated as ’Eris Lifesciences Limited‘ on January 25, 2007, subsequently changed to ’Eris Lifesciences Private Limited‘, and later converted into a public limited company in 2017. ERIS Lifesciences operates primarily in the pharmaceutical segment, supplying branded prescription products across chronic, sub-chronic and acute therapeutic areas that require high intervention of specialist and super-specialist doctors. Its manufacturing operations are based in India, with six manufacturing facilities across the country, while corporate functions are managed from its administrative offices in Ahmedabad. Over time, the company has expanded through acquisitions including the Indian branded formulations business of Strides Shasun Ltd for Rs 5000 crore, acquiring marketing rights for over 130 brands. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and EBITDA. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by API availability, pricing regulations, demand cycles in lifestyle therapy segments, and input cost fluctuations. 

b. Company Product Lines

• Tablets and Capsules
  o Used primarily by patients with chronic conditions such as diabetes, cardiovascular disease, and neurological disorders for daily oral medication.
• Oral Liquids
  o Supplies patients requiring liquid formulations for easier administration, including geriatric and pediatric populations across therapeutic areas. 
• Softgels
  o Provides a gelatin-based oral dosage form for drugs that require enhanced absorption or are insoluble in water.
• Ointments, Sprays and Gels
  o Serves patients with dermatological conditions, topical infections, and localized pain management through external application.
• Sterile Injectables
  o Used in hospital settings for critical care, oncology, and acute therapeutic interventions requiring parenteral administration.
• Biologics
  o Supplies patients with complex chronic diseases requiring advanced biologic therapies derived from living organisms.
• Vitamins and Minerals
  o Serves the nutraceutical segment for general wellness, maternal nutrition, and specific nutritional deficiencies.

The product portfolio is structured to serve both domestic patient demand across India and select international markets. 

c. Company Revenue Model

• Domestic Branded Formulations Revenue
  o Revenue generated through sales of prescription pharmaceutical products tostockists, distributors, and retail pharmacies across India. 
• Patient Care Initiatives Revenue
  o Contribution from offering various healthcare solutions to patients, including patientassistance programs and adherence support. 
• International Operations Revenue
  o Income from manufacturing unit approvals by stringent regulatory authorities enabling entry into pharmaceutical markets outside India.

Revenue performance is primarily influenced by prescription demand from super-specialist doctors, raw material costs including APIs, selling price realizations in domestic markets under drug price control regulation, and prescription volumes in chronic therapy segments. 

d. Geographic Presence

• Registered Office
  o Ahmedabad, Gujarat, India.
• Corporate Headquarters
  o Ahmedabad, Gujarat, India.
• Manufacturing Facilities
  o Six production plants located across India, including Guwahati and Ahmedabad.
• Distribution Network
  o Domestic distribution across India through a network of stockists and retail pharmacies covering multiple states.
• International Markets
  o Products supplied to select international markets depending on regulatory approvals including ANVISA for Brazil.

e. Key Milestones

• 2007: Incorporation of ERIS Lifescienceson January 25 in Ahmedabad, Gujarat.
  • 2007: Launch of ’Eris‘ division focused on cardiology and diabetes segment in September.
  • 2014: Set up manufacturing facility at Guwahati, Assam.
  • 2016: Acquisition of 100% equity shares of Aprica Healthcare Private Limited and 75.48% of Kinedex Healthcare Private Limited.
  • 2017: Launch of initial public offering on June 29, raising funds through offer for sale.
  • 2017: Acquisition of Indian branded formulations business of Strides Shasun Ltd for Rs 5000 crore in December.
  • 2025: Received ANVISA approval at Ahmedabad campus enabling entry into Brazil, the largest pharmaceutical market in South America. 

f. Industry Perspective

The pharmaceutical manufacturing industry is research-intensive and closely linked to demand from chronic disease management, acute care, and lifestyle therapy segments. Demand trends are influenced by disease prevalence, healthcare access, ageing population, and growth in branded generic prescriptions. The industry is also affected by fluctuations in raw material prices such as APIs and excipients, along with regulatory compliance costs for good manufacturing practices. Drug price control regulations and competition intensity increasingly shape pricing decisions and market access strategies. Companies in the sector must manage patent expiries, regulatory approvals, and distribution networks while maintaining product quality and supply chain reliability. These factors collectively influence financial performance and investor perception of firms like ERIS Lifesciences. 

ERIS Lifesciences Limited Stock Market Presence: Listings & Index Representation 

ERIS Lifesciences Limited is listed on the National Stock Exchange (NSE) under the symbol ERIS and on the Bombay Stock Exchange (BSE) with the scrip code 540596. ERIS Lifesciences share price is actively traded on both exchanges with a face value of Rs 1 per share. The company’s market presence is within the mid-cap segment of the market, given its market capitalization and industry standing. Due to its size and sector focus, ERIS Lifesciences stock price is generally tracked by investors interested in the branded pharmaceutical formulations industry. 

ERIS Lifesciences share price is part of several broad-based and sector-specific stock market indices, reflecting its position as a mid-cap pharmaceutical company in India. The company forms a part of benchmark indices such as the Nifty Midcap 100, BSE Midcap, and other broader indices. ERIS Lifesciences stock price also finds representation in sector-specific indices including the Nifty Pharma and BSE Healthcare indices. ERIS Lifesciences stock price movement relative to these indices provides context for understanding the company’s market standing. This presence helps investors track the stock relative to other branded generic pharmaceutical companies. 

ERIS Lifesciences Limited Stock Performance and Share Price History 

ERIS Lifesciences share price on the NSE reflects its position as a pure-play domestic branded pharmaceutical company specializing in lifestyle therapies in India. Its performance is qualitatively driven by factors such as new product launches, price increases taking effect, expansion in base business, EBITDA margin improvement through operational efficiency, and the ability to control employee and fixed expenses. Investors compare the stock’s current movement with other branded generic pharmaceutical companies to assess relative strength. ERIS Lifesciences share price movements become visible through real market movements across different time periods. 

ERIS Lifesciences stock price shows patterns during earnings-driven price changes. Broader sector strength has also supported the stock from time to time. Beyond operational and sector influences, corporate actions such as the company’s acquisition of Biocon‘s branded formulations portfolio, integration of acquired businesses, and receipt of regulatory approvals from stringent authorities can significantly affect ERIS Lifesciences share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by drug price controls and API supply chain disruptions. 

While short-term movements respond to events and announcements, longer-term valuation trends are captured by the stock’s annual high and low levels, offering context beyond daily or weekly changes. A notable peak in ERIS Lifesciences share price indicates stronger prescription growth and stable input costs, whereas a significant low aligns with market corrections or healthcare sector volatility. These extremes reflect the impact of drug pricing policies, global API price trends, and earnings visibility, providing a framework for understanding historical performance of ERIS Lifesciences stock price. 

ERIS Lifesciences share price behaviour mirrors the trading patterns of a mid-cap branded pharmaceutical company within India’s healthcare ecosystem. The company’s diversified product portfolio spanning oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology has shaped its price history. Over the past five years, ERIS Lifesciences share price has experienced periods of sharp gains followed by phases of consolidation. The stock reached its all-time high in June 2025 and its all-time low was reached in March 2020. ERIS Lifesciences stock price has shown moderate volatility compared to the overall market, with a beta coefficient of 0.30, indicating lower sensitivity to broader market movements. 

The company’s performance has closely tracked India’s chronic disease burden and increasing prevalence of lifestyle disorders. Positive momentum for ERIS Lifesciences share price appeared during periods of strong prescription growth in anti-diabetes and cardiovascular segments. However, periods of high API costs and drug price control measures have led to consolidation in ERIS Lifesciences share price. Profitability has faced headwinds due to increased interest costs following acquisitions, with net profit showing a declining trend over recent fiscal years, highlighting the capital-intensive nature of pharmaceutical acquisitions. 

ERIS Lifesciences price experienced a notable decline during challenging market conditions. A drop in prescription volumes from super-specialist doctors or deterioration in realizations under drug price control directly impacts profitability and leads to selling pressure, which pulls ERIS Lifesciences share price lower. Changes in government policy such as revisions in the National List of Essential Medicines or price caps on therapies under DPCO can also cause the stock to fall. Moreover, increases in raw material costs without corresponding price increases squeeze margins, making ERIS Lifesciences share price less attractive to market participants. 

Periods of economic slowdown that affect healthcare spending and out-of-pocket expenses raise concerns about prescription adherence, leading to price declines in ERIS Lifesciences share price. ERIS Lifesciences price is sensitive to API price movements. If sourcing costs from API suppliers rise significantly, it can cause the stock to fall as investors adjust expectations for future margin growth. Broader market sell-offs in mid-cap stocks also pull ERIS Lifesciences share price down, regardless of the company’s individual performance. 

Lower organic growth or reduced integration benefits from acquired businesses directly impacts revenue, resulting in a lower valuation for ERIS Lifesciences price. The company has faced headwinds from fluctuating API costs, increased competitive pressures from larger pharmaceutical players, and high interest costs from debt-funded acquisitions. ERIS Lifesciences price has also been affected by the need to continually invest in new product development and manufacturing upgrades to maintain quality standards. The company has seen net profit decline significantly over recent years, reflecting the impact of acquisition-related interest costs on bottom-line performance. 

The company maintains a strong focus on its core chronic therapy segments while exploring opportunities to expand into emerging therapies like dermatology, insulins, women’s health, CNS, oncology, and nephrology. ERIS Lifesciences price has shown that the company’s strategy of building a diversified presence across super-specialties and investing in patient care initiatives has provided growth opportunities during favourable pharmaceutical cycles. However, the competitive landscape and the presence of larger pharmaceutical players with significant scale advantages continue to influence ERIS Lifesciences price movements. ERIS Lifesciences price remains closely watched by market participants for signals about prescription growth and regulatory developments. 

ERIS Lifesciences Limited Investor Relevance and Role in Portfolio 

ERIS Lifesciences price is relevant for investors seeking exposure to the pharmaceutical sector with a focus on pure-play domestic branded formulations and chronic lifestyle therapies. The company’s inclusion in mid-cap and pharma indices underscores its importance in India’s branded generic pharmaceutical space. ERIS Lifesciences position as the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model, together with its presence across nine super-specialties including Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care, makes it a consideration for long term allocations. 

ERIS Lifesciences price is influenced by the company’s ownership structure. The company’s equity is held by a broad mix of promoters, institutional investors, mutual funds, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of 53.92 per cent, reflecting strong internal control under the leadership of Amit Indubhushan Bakshi. Foreign institutional investors hold 6.39 per cent of the company’s shares. Mutual funds hold 18.22 per cent, representing significant institutional participation. Financial institutions hold 2.13 per cent. The general public holds the remaining stake of 10.06 per cent, while other investors hold 9.26 per cent. The company’s management includes Amit Indubhushan Bakshi as Chairman and Managing Director, Milind Talegaonkar as Company Secretary and Compliance Officer, and other named executive directors. This investor base, with stable promoter participation and significant institutional holdings, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing. 

Beyond fundamentals and ownership, ERIS Lifesciences price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on API prices, prescription growth, and regulatory policy actions. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements from the National Pharmaceutical Pricing Authority and drug regulatory bodies. 

Technical indicators provide additional insight into short term momentum shifts in ERIS Lifesciences price. While these indicators are primarily used for near term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s beta of 0.30 indicates lower volatility compared to the broader market, suggesting that ERIS Lifesciences price movements may be less pronounced relative to the overall index. 

Overall, ERIS Lifesciences price demonstrates a low volatility profile that makes it less sensitive to broader market movements, while still being sensitive to sector specific factors such as API price fluctuations, drug pricing regulations, prescription volumes, and competitive dynamics in the branded generic industry. The company’s debt to equity ratio reflects its use of leverage in funding acquisitions and capital expenditure. Return on equity and return on capital employed are measured at certain levels, and the company’s book value per share serves as a reference point for valuation assessments by market participants. 

ERIS Lifesciences Limited Sectoral Relevance and Peer Positioning 

ERIS Lifesciences Limited sector relevance stems from its nearly two-decade presence in the branded pharmaceutical industry, its position as the youngest company among the top 20 pharma companies in India, its pure-play domestic branded formulations business model, its portfolio across chronic, sub-chronic and acute therapeutic areas requiring high intervention of super-specialist doctors, its presence in flagship therapies such as oral anti-diabetes, cardiovascular disease, and vitamins/minerals/nutrients, its emerging therapies including dermatology, insulins, women’s health, central nervous system, oncology, and nephrology, its six manufacturing facilities across India with approvals from stringent regulatory authorities, its network of stockists and retail pharmacies pan-India, its patient care initiatives platform providing various healthcare solutions, and its track record of successful acquisitions including Strides‘ branded formulations business and Biocon‘s diabetes portfolio, establishing it as a focused mid-cap branded pharmaceutical provider supporting India‘s chronic disease management ecosystem. ERIS Lifesciences price is compared with peers like Torrent Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy‘s Laboratories, Cipla, Divis Laboratories, and Jubilant Pharmova. These comparisons focus on product portfolio composition, therapeutic area diversification, manufacturing capabilities, and regulatory approvals rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API price trends, prescription demand patterns, and government pharmaceutical pricing policies further highlights ERIS Lifesciences positioning within India’s broader branded generic pharmaceutical market. 

ERIS Lifesciences market cap reflects its position as a mid-cap player within India‘s pharmaceutical sector. Based on available data, the company’s market capitalization fluctuates within a range depending on the reporting period. The market cap has moved in line with investor perceptions of the company’s growth potential following various market cycles. From earlier years through more recent periods, the market cap showed an increasing trend as the company expanded its brand portfolio through acquisitions and strengthened its super-specialty presence, followed by periods of consolidation. This pattern reflects strong investor confidence during favourable prescription growth cycles, followed by contraction during challenging periods impacted by drug pricing pressures and regulatory changes. This movement mirrors the pattern in ERIS Lifesciences price from its various levels over time. 

ERIS Lifesciences earnings trajectory demonstrates the impact of its operational execution and acquisition strategy in a competitive pharmaceutical industry. In recent fiscal years, total income showed strong growth supported by the core branded formulations business and contribution from acquired portfolios. Based on available data, the company’s revenue from operations increased from the previous fiscal year to the most recent fiscal year, showing healthy growth in total income over that period. However, profit after tax declined significantly due to high interest costs and depreciation expenses associated with acquisitions, impacting net profitability. The company has faced headwinds from fluctuating API costs, increased competitive pressures from larger pharmaceutical players, high interest costs from debt-funded acquisitions, and ongoing integration expenses. However, the company has continued to expand its therapeutic presence across super-specialties and expects to benefit from growing chronic disease burden in India. These developments illustrate the capital-intensive nature of pharmaceutical acquisitions and the company’s position within this sector. ERIS Lifesciences price has moved in response to these earnings patterns. 

ERIS Lifesciences EPS provides insight into its operational performance and income generation from branded formulations across super-specialty therapy areas. Based on available data, the company reported a basic EPS in certain recent quarters showing certain patterns compared to previous periods. The trailing twelve month EPS stands at a certain level. The company’s EPS for the last full fiscal year was lower compared to the prior fiscal year, reflecting the impact of acquisition-related costs on bottom line. The company has a low face value per share of Re 1 and is promoted by Amit Indubhushan Bakshi. More recent quarterly performance suggests that EPS has shown certain movements as the company manages its interest costs and integration expenses. ERIS Lifesciences price has reflected these EPS trends over time. 

ERIS Lifesciences P/E ratio reflects how investors perceive the company‘s earnings relative to its revenue streams from branded formulations across diabetes, cardiovascular, and other super-specialty therapies. Based on available data, the current P/E ratio stands at a certain level relative to the industry average. The company’s profit after tax declined from the previous fiscal year to the most recent fiscal year. However, quarterly performance has shown certain patterns, with profit after tax and total income showing changes on a quarter on quarter basis. The company’s earnings before interest and taxes for recent periods stood at certain levels with corresponding margins. The net profit margin showed certain changes in recent quarters compared to earlier periods. Overall, these changes highlight how market sentiment evolves alongside the company’s operational performance in a cyclical industry. ERIS Lifesciences price has moved in line with these valuation changes. 

Summary 

ERIS Lifesciences operates as a mid-cap pure-play domestic branded pharmaceutical company specializing in lifestyle therapies across nine super-specialties in India. ERIS Lifesciences price movements reflect the company’s prescription growth from super-specialist doctors and API cost management. ERIS Lifesciences price is influenced by drug pricing regulations, API supply cycles, and competitive dynamics in the branded generic industry. The company is the youngest among the top 20 pharma companies in India and manufactures products across six facilities with approvals from stringent authorities. Promoters hold a stable majority stake of 53.92 per cent in the company.